Thoracic Oncology
BioNTech SE focuses on advanced non-small cell lung cancer and small-cell lung cancer, including first-line, relapsed, and metastatic settings. Its trials also address broader advanced lung cancer populations and treatment-resistant disease.
- Non-small cell lung cancer
- Small-cell lung cancer
- Advanced lung cancer
- Metastatic solid tumors
Research in this area includes combination immunotherapy approaches and regimens paired with chemotherapy for patients with advanced thoracic malignancies.
Gastrointestinal and Hepatopancreatic Malignancies
The sponsor studies metastatic colorectal cancer, rectal cancer, colon cancer, and pancreatic ductal adenocarcinoma in both unresectable and post-surgical settings. These programs extend to advanced solid tumors with gastrointestinal involvement.
- Metastatic colorectal cancer
- Rectal cancer
- Colon cancer
- Pancreatic ductal adenocarcinoma
Investigations include adjuvant therapy after resection and treatment strategies for microsatellite stable or mismatch repair proficient disease.
Breast, Gynecologic, and HER2-Directed Oncology
BioNTech SE has active trials in advanced breast cancer, metastatic breast cancer, triple-negative breast cancer, and endometrial cancer. The portfolio includes tumors with HER2 expression and recurrent disease requiring new treatment options.
- Triple-negative breast cancer
- Metastatic breast cancer
- Recurrent endometrial cancer
- HER2-expressing solid tumors
Trial activity in this domain also covers ovarian cancer and other gynecologic malignancies with biomarker-defined profiles.
Head and Neck, Skin, and Biomarker-Selected Solid Tumors
The sponsor studies head and neck squamous cell carcinoma, including unresectable, metastatic, and recurrent disease, as well as melanoma and other advanced solid tumors. Several programs are directed by tumor-associated markers such as HPV16, PD-L1, and CLDN6.
- Head and neck squamous cell carcinoma
- Melanoma
- CLDN6-positive tumors
- Biomarker-selected solid tumors
These studies include patients with metastatic or unresectable disease across multiple solid tumor types.
Infectious Disease and Vaccinology
Beyond oncology, BioNTech SE funds research in HIV-1 infection and tuberculosis. These programs reflect interest in immune-based approaches to infectious disease prevention and treatment.
- HIV-1 infection
- Tuberculosis
- RNA-based vaccines
The sponsor’s non-oncology research also includes vaccine-oriented studies relevant to infectious disease immunology.
